FSD Pharma Inc. (HUGE) News

FSD Pharma Inc. (HUGE): $1.00

0.04 (+4.17%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter HUGE News Items

HUGE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest HUGE News From Around the Web

Below are the latest news stories about FSD Pharma Inc that investors may wish to consider to help them evaluate HUGE as an investment opportunity.

FSD Pharma Unveils Newly Designed Website

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. FSD Pharma (NASDAQ: HUGE ) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the launch of its newly designed website . According to the update, the new site conveys the companys emerging position within the biopharmaceutical industry and its ongoing commitment to bring novel treatment solutions for brain and inflammatory disorders to millions of patients in need. We have strategically assembled a team of scientists to help develop our powerful pipeline of next-generation therapeutics, said Anthony Durkacz, interim CEO of FSD Pharma. With some of the greatest min...

Benzinga | January 20, 2022

FSD Pharma Announces Launch of New Corporate Website

New Website Shares FSD''s Unique Drug Pipeline and Vision to Improve the Quality of Life for Patients Suffering from Brain & Inflammatory Disorders FSD Pharma Inc. (NASDAQ: HUGE ) (CSE: HUGE ) (FRA: 0K9A) (" FSD Pharma " or the " Company "), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today the launch of its newly designed website. The new site conveys the Company''s emerging position within the biopharmaceutical industry and its ongoing commitment to bring novel treatment solutions for brain and inflammatory disorders to millions of patients in need. To view the website, please visit www.fsdpharma.com . "We have strategically assembled a team of scientists to help develop our powerful pipeline of next-generation therapeut...

Benzinga | January 20, 2022

FSD Pharma Congratulates Dr. Eleanor Fish on Being Named to the Order of Canada

TORONTO, January 18, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, warmly congratulates Eleanor N. Fish, Ph.D., a member of its Research and Clinical Advisory Board, on her appointment to the Order of Canada.

Yahoo | January 18, 2022

FSD Pharma to Present at the H.C. Wainwright Bioconnect Conference on January 10-13th

TORONTO, January 04, 2022--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that Anthony Durkacz, Interim CEO of FSD Pharma, will present at the H.C. Wainwright Bioconnect Conference to be held virtually on January 10-13, 2022. Mr. Durkacz’s presentation will be available on-demand for conference attendees starting at 7:00 a.m. ET on January 10

Yahoo | January 4, 2022

FSD Pharma Announces Share Repurchase Program

TORONTO, December 30, 2021--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that its Board of Directors has authorized the repurchase by the Company of up to 2,000,000 of its Subordinate Class B Voting Shares (the "Subordinate Voting Shares") from time to time over the next 12 months at prevailing market prices in order to allow the Company to

Yahoo | December 30, 2021

FSD Pharma Establishes New Regulatory Advisory Board with the Appointment of Joga Gobburu, Ph.D., and Mary Melnyk, Ph.D., as Members

TORONTO, December 09, 2021--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that it has formed a Regulatory Advisory Board ("RAB") and has appointed Joga Gobburu, B.Pharm. (Hons), M.Sc. (Hons), Ph.D., M.B.A., and Mary Melnyk, M.Sc., Ph.D., as members.

Yahoo | December 9, 2021

InvestmentPitch.com: InvestmentPitch Media Video Discusses FSD Pharma''s Unveiling of Video Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical Mouse Models - Video Available on Investmentpitch.com

Vancouver, British Columbia--(Newsfile Corp. - December 3, 2021) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of asse

FinanzNachrichten | December 3, 2021

FSD Pharma to Present at the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th

TORONTO, December 03, 2021--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that Anthony Durkacz, Interim CEO of FSD Pharma, will present at the H.C. Wainwright 2nd Annual Virtual Psychedelics Conference to be held on December 6, 2021. Mr. Durkacz’s presentation will be available on-demand for conference attendees starting at 7:00 a.m. ET and a

Yahoo | December 3, 2021

InvestmentPitch Media Video Discusses FSD Pharma's Unveiling of Video Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical Mouse Models - Video Available on Investmentpitch.com

Vancouver, British Columbia--(Newsfile Corp. - December 3, 2021) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, is now sharing pre-clinical data demonstrating the potentially disease-modifying effects of Lucid-MS, the company's lead drug candidate for the potential treatment of multiple sclerosis in the animal models of MS.InvestmentPitch.com has produced a "video" which discusses this n

Yahoo | December 3, 2021

FSD Pharma (CSE:HUGE) demonstrates positive effects of Lucid-MS in treating MS in pre-clinical models

FSD Pharma (HUGE) is sharing pre-clinical data demonstrating the potentially disease-modifying effects… The post FSD Pharma (CSE:HUGE) demonstrates positive effects of Lucid-MS in treating MS in pre-clinical models appeared first on The Market Herald .

The Market Herald | December 2, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6711 seconds.